October 13th, 2016 — UPDATE –Seattle Genetics announces two new compounds in their cancer research: https://twitter.com/SeattleGenetics
Clay Siegall, Ph.D., co-founder of Seattle Genetics in 1998, is not only the company’s current President, CEO, and Chairman for the Board of Directors, but also was he appointed to Mirna Therapeutics and serves as a member of the Board of Directors as an outside director. Mirna Therapeutics, a biotechnology company, focuses on microRNA (miRNA) a therapy which is a great working relationship for both companies.
With Dr. Siegall’s guidance and experience, the company has created antibody-based therapies for these individuals. Dr. Siegall successfully adds to his 15 patents he holds and continues to publish scientific articles, to add to his 70+ published works he currently holds as well. His education and authority in the biotechnology realm stems from his education at both University of Maryland, where he obtained a Bachelor in Science in Zoology, and Ph.D. at George Washington University in Genetics.
With his education behind him, Dr. Siegall went on to work for the National Institutes of Health, National Cancer Institute, and then Bristol-Myers Squibb Pharmaceutical Research Institute, prior to starting Seattle Genetics. Seattle Genetics has secured more than $675 million through public and private funding. By securing this type of funding it has allowed Seattle Genetics to move forward on therapies, such as ADCETRIS (brentuximab vedotin), for antibody-based cancer therapy in 2011, in which the FDA granted accelerated approval for treatment. Fortunately, Seattle Genetics has a diverse product pipeline to help patients find the treatments needed.